CBT
CABOT CORP
NYSE · Basic Materials · Chemicals - Specialty · US
$73.46
−1.12%Year over year
Reported trailing growth
- Revenue
- -4.7%
- EBITDA
- -14.9%
- EBIT
- -21.0%
- EPS
- -53.2%
- Free cash flow
- -19.3%
- Operating cash flow
- -23.5%
Forward estimates
Based on analyst estimates
- Revenue
- +1.7%
- EBITDA
- +17.5%
- EPS
- +98.1%
Three-year CAGR
- Revenue
- -4.9%
- EBITDA
- +13.9%
- EBIT
- +16.9%
- Net income
- +16.6%
- EPS
- +18.5%
- Free cash flow
- +5.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026